EGFR and non-small cell lung carcinoma: It was based on the results of a multicenter, open‐label, randomized, Phase III study (ENSURE), which aimed to compare the efficacy and safety of erlotinib to gemcitabine plus cisplatin as first‐line treatment for stage IIIB/IV EGFR‐mutation positive NSCLC patients.71